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Appendix Figure 1: The LDL-C (mmol/L) effect of 4
PCSK9 SNPs per LDL-C decreasing allele.
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Appendix Figure 2: Associations of a PCSK9 gene-centric score (GS) with cancers.
Effect estimates are presented as odds ratios (OR), with 95% confidence interval (CI)
scaled to a mmol/L decrease in LDL-C (mmol/L). Results are pooled using a fixed
effect model. The size of the black squares are proportional to the inverse of the
variance.
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Appendix Figure 3: Associations of a PCSK9 gene-centric score (GS) with myocardial
infarction or type 2 diabetes, and LDL-C. Effect estimates are presented as odds ratios
(OR) or mean differences, with 95% confidence interval (CI). r = Pearson’s correlation
coefficient was estimated using a weighted linear regression.
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Appendix Figure 4: Associations of a PCSK9 gene-centric score (GS) with ischemic or
hemorrhagic stroke, and LDL-C. Effect estimates are presented as odds ratios (OR) or
mean differences, with 95% confidence interval (CI). r = Pearson’s correlation coeffi-
cient was estimated using a weighted linear regression.
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support from the British Heart Foundation (FS/14/55/30806).
ISGS: Ischemic Stroke Genetics Study (ISGS)/Siblings With Ischemic Stroke Study (SWISS)
was supported in part by the Intramural Research Program of the NIA, NIH project Z01 AG-
000954-06. ISGS/SWISS used samples and clinical data from the NIH-NINDS Human Genetics
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Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/ninds), human subjects
protocol numbers 2003-081 and 2004-147. ISGS/SWISS used stroke-free participants from the
Baltimore Longitudinal Study of Aging (BLSA) as controls. The inclusion of BLSA samples was
supported in part by the Intramural Research Program of the NIA, NIH project Z01 AG-000015-
50, human subjects protocol number 2003-078. The ISGS study was funded by NIH-NINDS
Grant R01 NS-42733 (J F Meschia). The SWISS study was funded by NIH-NINDS Grant R01
NS-39987 (J F Meschia). This study used the high-performance computational capabilities of
the Biowulf Linux cluster at the NIH (http://biowulf.nih.gov).
MGH-GASROS: MGH Genes Affecting Stroke Risk and Outcome Study (MGH-GASROS)
was supported by NINDS (U01 NS069208), the American Heart Association/Bugher Founda-
tion Centers for Stroke Prevention Research 0775010N, the NIH and NHLBI’s STAMPEED
genomics research program (R01 HL087676), and a grant from the National Center for Research
Resources. The Broad Institute Center for Genotyping and Analysis is supported by grant U54
RR020278 from the National Center for Research resources.
MILANO: Milano - Besta Stroke Register Collection and genotyping of the Milan cases within
CEDIR were supported by the Italian Ministry of Health (Grant Numbers: RC 2007/LR6, RC
2008/LR6; RC 2009/LR8; RC 2010/LR8; GR-2011-02347041). FP6 LSHM-CT-2007-037273 for
the PROCARDIS control samples.
WTCCC2: Wellcome Trust Case-Control Consortium 2 (WTCCC2) was principally funded
by the Wellcome Trust, as part of the Wellcome Trust Case Control Consortium 2 project
(085475/B/08/Z and 085475/Z/08/Z and WT084724MA). The Stroke Association provided ad-
ditional support for collection of some of the St George’s, London cases. The Oxford cases were
collected as part of the Oxford Vascular Study which is funded by the MRC, Stroke Association,
Dunhill Medical Trust, National Institute of Health Research (NIHR) and the NIHR Biomedical
Research Centre, Oxford. The Edinburgh Stroke Study was supported by the Wellcome Trust
(clinician scientist award to C Sudlow), and the Binks Trust. Sample processing occurred in
the Genetics Core Laboratory of the Wellcome Trust Clinical Research Facility, Western Gen-
eral Hospital, Edinburgh. Much of the neuroimaging occurred in the Scottish Funding Council
Brain Imaging Research Centre (www.sbirc.ed.ac.uk), Division of Clinical Neurosciences, Uni-
versity of Edinburgh, a core area of the Wellcome Trust Clinical Research Facility and part
of the SINAPSE (Scottish Imaging Network-A Platform for Scientific Excellence) collaboration
(www.sinapse.ac.uk), funded by the Scottish Funding Council and the Chief Scientist Office.
Collection of the Munich cases and data analysis was supported by the Vascular Dementia Re-
search Foundation. M Farrall and A Helgadottir acknowledge support from the BHF Centre of
Research Excellence in Oxford and the Wellcome Trust core award (090532/Z/09/Z).
VISP: The GWAS component of the Vitamin Intervention for Stroke Prevention (VISP) study
was supported by the United States National Human Genome Research Institute (NHGRI),
Grant U01 HG005160 (PI Miche`le Sale & Bradford Worrall), as part of the Genomics and Ran-
domized Trials Network (GARNET). Genotyping services were provided by the Johns Hopkins
University Center for Inherited Disease Research (CIDR), which is fully funded through a fed-
eral contract from the NIH to the Johns Hopkins University. Assistance with data cleaning was
provided by the GARNET Coordinating Center (U01 HG005157; PI Bruce S Weir). Study re-
cruitment and collection of datasets for the VISP clinical trial were supported by an investigator-
initiated research grant (R01 NS34447; PI James Toole) from the United States Public Health
Service, NINDS, Bethesda, Maryland. Control data obtained through the database of genotypes
and phenotypes (dbGAP) maintained and supported by the United States National Center for
Biotechnology Information, US National Library of Medicine.
WHI: Funding support for WHI-GARNET was provided through the NHGRI GARNET (Grant
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Number U01 HG005152). Assistance with phenotype harmonisation and genotype cleaning, as
well as with general study coordination, was provided by the GARNET Coordinating Center
(U01 HG005157). Funding support for genotyping, which was performed at the Broad Institute
of MIT and Harvard, was provided by the NIH Genes, Environment, and Health Initiative (GEI;
U01 HG004424).
SiGN: The Stroke Genetics Network (SiGN) study was funded by a cooperative agreement
grant from the National Institute of Neurological Disorders and Stroke (NINDS) U01 NS069208.
Genotyping services were provided by the Johns Hopkins University Center for Inherited Disease
Research (CIDR), which is fully funded through a federal contract from the National Institutes
of Health (NIH) to the Johns Hopkins University (contract No.HHSN268200782096C). The Bio-
statistics Department Genetics Coordinating Center at the University of Washington (Seattle)
provided more extensive quality control of the genotype data through a subcontract with CIDR.
Additional support to the Administrative Core of SiGN was provided by the Dean’s Office, Uni-
versity of Maryland School of Medicine. This work was supported by grants received from the
German Federal Ministry of Education and Research (BMBF) in the context of the e:Med pro-
gram (e:AtheroSysMed, the FP7 European Union project CVgenes@target (261123), the DFG
as part of the CRC 1123 (B3), the Corona Foundation and the Fondation Leducq (Transatlantic
Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain).
Online only methods
International Genomics of Alzheimer’s Project (IGAP) is a large two-stage study based upon
genome-wide association studies (GWAS) on individuals of European ancestry. In stage 1, IGAP
used genotyped and imputed data on 7,055,881 single nucleotide polymorphisms (SNPs) to
meta-analyse four previously-published GWAS datasets consisting of 17,008 Alzheimer’s disease
cases and 37,154 controls (The European Alzheimer’s disease Initiative - EADI the Alzheimer
Disease Genetics Consortium - ADGC The Cohorts for Heart and Aging Research in Genomic
Epidemiology consortium - CHARGE The Genetic and Environmental Risk in AD consortium -
GERAD). In stage 2, 11,632 SNPs were genotyped and tested for association in an independent
set of 8,572 Alzheimer’s disease cases and 11,312 controls. Finally, a meta-analysis was performed
combining results from stages 1 & 2.
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